Clinical Trial

JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Trial Details
NCT Number NCT07115706
Lead Sponsor Jeil Pharmaceutical Co., Ltd.
Conditions Erosive Gastroesophageal Reflux Disease
Enrollment 7,150 participants
Start Date 2025-08-25
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-14